Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

33.37
-0.4800-1.42%
Post-market: 34.020.6500+1.95%19:42 EDT
Volume:1.38M
Turnover:46.09M
Market Cap:2.65B
PE:40.70
High:33.91
Open:33.03
Low:32.73
Close:33.85
52wk High:50.71
52wk Low:22.61
Shares:79.46M
Float Shares:78.23M
Volume Ratio:1.36
T/O Rate:1.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:5.34%
ROA:2.91%
PB:2.02
PE(LYR):40.70

Loading ...

Veracyte Initiated at Hold by Canaccord Genuity

Dow Jones
·
Oct 20, 2025

Veracyte initiated with a Hold at Canaccord

TIPRANKS
·
Oct 20, 2025

Veracyte (VCYT): Assessing Valuation After Recent Momentum and Share Price Rebound

Simply Wall St.
·
Oct 18, 2025

Veracyte Initiated at Buy by Freedom Capital Markets

Dow Jones
·
Oct 17, 2025

Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets

TIPRANKS
·
Oct 17, 2025

Veracyte initiated with a Buy at Freedom Capital

TIPRANKS
·
Oct 17, 2025

Press Release: Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Dow Jones
·
Oct 16, 2025

Veracyte (VCYT): Assessing Valuation After BALANCE Trial Data and Analyst Upgrades Boost Investor Confidence

Simply Wall St.
·
Oct 11, 2025

Veracyte Inc. Chief Scientific & Medical Officer Phillip G. Febbo Reports Disposal of Common Shares

Reuters
·
Oct 08, 2025

Veracyte Inc. SVP, General Counsel Annie McGuire Reports Disposal of Common Shares

Reuters
·
Oct 04, 2025

Veracyte Inc. Director Robert S. Epstein Reports Disposal of Common Shares

Reuters
·
Oct 04, 2025

Veracyte announces results from BALANCE trial of PAM50

TIPRANKS
·
Sep 29, 2025

Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Reuters
·
Sep 29, 2025

Veracyte Announces That Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men With Recurrent Prostate Cancer

THOMSON REUTERS
·
Sep 29, 2025

Veracyte to Present First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Recurrent Prostate Cancer at ASTRO 2025

Reuters
·
Sep 24, 2025

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men With Recurrent Prostate Cancer Will Be Presented at Astro 2025

THOMSON REUTERS
·
Sep 24, 2025

Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Reuters
·
Sep 09, 2025